Topic:

Emerging Markets

Latest Headlines

Latest Headlines

Sanofi faces bribery allegations from China whistleblower

Sanofi has joined GlaxoSmithKline in facing bribery allegations in China. According to a Chinese newspaper, the whistleblower says Sanofi paid 1.7 million yuan in bribes to 503 doctors around the country.

Ranbaxy gets site for second Malaysian plant

India's Ranbaxy Laboratories has been manufacturing drugs in Malaysia since before anyone was talking about emerging markets. Now, it is about ready to expand on that position with a second plant in the country.

GE snags Brazilian med tech outfit

GE Healthcare has bought Brazil's Omnimed, a producer of patient monitoring devices, part of the conglomerate's effort to increase its share of the Latin American market.

China revokes patent on Gilead's Viread

In another swipe at the intellectual property of drugmakers in emerging markets, China's State Intellectual Property Office (SIPO) has yanked the patent for Viread, saying it lacks novelty.

GlaxoSmithKline CEO's reform-minded rep under fire in China probe

As the company's current scandal in China shows, Witty was caught somewhat flat-footed by problems there, and some investors wonder whether Witty's reforms have been rigorous enough.

Hypermarcas leaps ahead in Brazil with surprise profits, sales surge

Brazilian drugmaker Hypermarcas shows that market savvy pays, even when an economy hits the skids. Despite an unexpected lag in GDP growth, Hypermarcas posted a surprise profit for the second quarter. A sales surge helped swing the company into the black, with pharma sales alone up 13.3%.

Stryker CEO: So far, so good after one year

Stryker's Kevin Lobo came aboard after the surprise ouster of Stephen MacMillan, and, in his first year at the helm of the Michigan device giant, the CEO has presided over a huge Chinese buyout, a lasting recall sting and expansions into new markets.

Baxter caught up in China bribery scandal

Big Pharma companies are fighting to stay out of the spotlight as authorities show up to visit them.

'Brazil generics issue' costs Sanofi nearly as much as patent losses

Because Sanofi has been investing heavily in emerging markets in recent years to help it offset revenue declines from patent expirations, a 2.3%  crash in sales in those markets was a big surprise.

WSJ: Baxter acknowledges it found irregular payments by China joint venture

Baxter uncovered expense violations in July 2012 from a joint venture in China, which went undisclosed until the WSJ contacted it with an anonymous tipster's information that employees at the venture fabricated conferences as part of a bribery scheme.